ÂÜÀòÂÒÂ×

Mamoun Alhamadsheh, PharmD, PhD, is a scientific co-founder of Eidos Therapeutics. He is an associate professor of pharmaceutical chemistry at the University of the Pacific. His NIH-funded research group employs an interdisciplinary approach to study protein misfolding diseases, combining synthetic organic chemistry with biochemistry and molecular biology. He is an expert in structure-based design of novel therapeutic agents for diseases associated with transthyretin amyloidosis. Dr. Alhamadsheh, in collaboration with Dr. Isabella Graef, led the research effort that resulted in the discovery of AG10, the lead molecule for Eidos Therapeutics, and he continues to advise the scientific direction of the company. Another active area of research in Dr. Alhamadsheh’s group is developing novel technologies for drug targeting and delivery. Dr. Alhamadsheh is the recipient of a New Investigator Award from the American Association of Colleges of Pharmacy. He is a coauthor on multiple publications and an inventor on several issued and pending patents. Dr. Alhamadsheh holds a PhD in medicinal chemistry from the University of Toledo and performed his post-doctoral research in the area of chemical biology at Stanford University.